- Home
- TEI vs IMRX Comparison
TEI vs IMRX Comparison
Compare TEI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | IMRX |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.9M | 340.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TEI | IMRX |
|---|---|---|
| Price | $6.06 | $5.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 250.8K | ★ 763.7K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.78 | $1.10 |
| 52 Week High | $7.00 | $10.08 |
Technical Indicators
Market Signals| Indicator | TEI | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 57.31 |
| Support Level | $5.85 | $5.34 |
| Resistance Level | $6.18 | $5.80 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 44.78 | 84.78 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.